Regulated information Paris, February 23, 2026 DISCLOSURE FISCAL 2026/16 OF TRANSACTIONS ON TREASURY SHARES Period of: February 16 to February 20, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO8516-Feb-26NL0015001W4936 50011,1496XPAR213800RQNIQT48SEEO85<td style="width:95.67px;;t ...

Company Overview - Pluxee is a global player in Employee Benefits and Engagement, operating in 28 countries [3] - The company offers a broad range of solutions across Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [3] - Pluxee has over 5,600 engaged team members and serves more than 500,000 clients, 37 million+ consumers, and 1.7 million+ merchants [3] - The company has been in business for more than 45 years and is committed to creating a positive impact on local communities and supporting employee well-being [3] Treasury Share Transactions - The disclosure period for treasury share transactions was from February 9 to February 13, 2026 [1] - On February 9, 2026, a total of 70,000 shares were acquired across three platforms at prices ranging from €11.5323 to €11.5681 [2] - On February 10, 2026, a total of 70,095 shares were acquired at prices between €12.0429 and €12.0649 [2] - On February 11, 2026, a total of 75,000 shares were acquired at prices between €11.3685 and €11.3924 [2] - On February 12, 2026, a total of 75,189 shares were acquired at prices between €11.1763 and €11.1794 [2] - On February 13, 2026, a total of 75,800 shares were acquired at prices between €11.1379 and €11.1501 [2]

Core Insights - Pluxee N.V. disclosed transactions on treasury shares for the period from February 2 to February 6, 2026, indicating ongoing share buyback activities [1]. Group 1: Treasury Share Transactions - On February 2, 2026, a total of 74,377 shares were acquired across three platforms, with an average price ranging from €11.1807 to €11.2610 [2]. - On February 3, 2026, 76,150 shares were acquired, with average prices between €11.0596 and €11.1065 [2]. - On February 4, 2026, 73,450 shares were acquired, with average prices from €11.4615 to €11.5179 [2]. - On February 5, 2026, 74,500 shares were acquired, with average prices between €11.3378 and €11.3987 [2]. - On February 6, 2026, 75,000 shares were acquired, with average prices ranging from €11.1565 to €11.2828 [2]. Group 2: Company Overview - Pluxee operates in 28 countries, focusing on Employee Benefits and Engagement, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [3]. - The company has over 5,600 engaged team members and serves more than 500,000 clients, impacting over 37 million consumers and 1.7 million merchants [3]. - With over 45 years of experience, Pluxee is dedicated to creating a positive impact on local communities and promoting employee well-being [3].

Core Insights - Polaryx Therapeutics is advancing its investigational therapy PLX-200 for Krabbe disease, presenting new data at the 22nd Annual WORLDSymposium™ [1][2] - The SOTERIA trial, a Phase 2 study, aims to assess the safety and efficacy of PLX-200 across multiple lysosomal storage disorders (LSDs) [2][5] Company Overview - Polaryx Therapeutics is a clinical-stage biotechnology company focused on developing therapies for rare orphan lysosomal storage disorders, founded in 2014 [7] - The company aims to deliver patient-friendly treatments that address the underlying pathophysiology of these diseases [7] Product Information - PLX-200 is an orally available compound based on gemfibrozil, which has been used in adults but never approved for pediatric indications [4] - The drug's ability to cross the blood-brain barrier positions it as a potential treatment for multiple rare LSDs [4] Clinical Trial Details - The SOTERIA trial will include patients with CLN2, CLN3, Krabbe disease, and Sandhoff disease, representing about 25% of the LSD population [5] - The trial is designed to be flexible and resource-efficient, with plans to initiate in the first half of 2026 [5][6] Presentation Information - Shrijay Vijayan, Chief Scientific and Business Development Officer, will present preclinical findings on PLX-200 in a mouse model of Krabbe disease on February 6, 2026 [3]

Core Insights - Pluxee N.V. disclosed transactions on treasury shares for the period from January 26 to January 30, 2026, indicating ongoing share buyback activities [1][2]. Group 1: Treasury Share Transactions - On January 26, 2026, Pluxee acquired a total of 75,000 shares across three platforms, with an average price ranging from €11.0542 to €11.1310 [2]. - On January 27, 2026, the company purchased 75,481 shares, with average prices between €11.1202 and €11.1415 [2]. - On January 28, 2026, a total of 69,000 shares were acquired, with average prices from €10.9400 to €11.4209 [2]. - On January 29, 2026, Pluxee bought 75,000 shares, with average prices ranging from €11.2227 to €11.2795 [2]. - On January 30, 2026, the company acquired 67,664 shares, with average prices between €11.0811 and €11.1280 [2]. Group 2: Company Overview - Pluxee operates in 28 countries, focusing on Employee Benefits and Engagement, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [3]. - The company has over 5,600 engaged team members and serves more than 500,000 clients, impacting over 37 million consumers and 1.7 million merchants [3]. - With over 45 years of experience, Pluxee is dedicated to creating a positive impact on local communities and promoting employee well-being [3].

Core Insights - Protalix Bio Therapeutics (PLX) has announced a significant regulatory and clinical milestone for its Fabry disease treatment in Europe, indicating positive progress in its drug development efforts [1] Company Overview - Protalix Bio Therapeutics is focused on developing innovative therapies, particularly in the biotechnology sector, with an emphasis on unique mechanisms of action and first-in-class therapies [1] Market Context - The biotechnology sector is characterized by breakthrough science that can lead to substantial returns, but it also requires careful scrutiny due to inherent risks [1]

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company has a team of experienced news journalists who produce independent content across various financial markets [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The news team delivers insights across multiple sectors, including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Adoption - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Viewpoint - The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the 2mg/kg every-4-weeks dosing regimen of pegunigalsidase alfa for adult patients with Fabry disease, pending review by the European Commission, with a decision expected by March 2026 [1] Group 1: Company Updates - Chiesi Global Rare Diseases and Protalix BioTherapeutics announced the positive CHMP opinion, which aims to reduce the treatment burden for patients and their families by extending the time between infusions [2] - Protalix is eligible for a $25 million regulatory milestone payment from Chiesi if the new dosing regimen is approved by the European Commission [2] Group 2: Product Information - Pegunigalsidase alfa is intended for adult patients with Fabry disease who are stable on enzyme replacement therapy, and the positive opinion follows a re-examination of the dosing regimen application [1][2] - The CHMP's opinion is based on results from the BRIGHT study, which assessed the safety, efficacy, and pharmacokinetics of the alternative dosing regimen over 52 weeks [2] Group 3: Industry Context - Fabry disease is a rare inherited lysosomal storage disorder caused by mutations in the GLA gene, leading to serious health complications, including kidney failure and heart issues [3] - Early detection and access to appropriate treatments are critical for managing symptoms and slowing disease progression in Fabry disease [3]

Core Viewpoint - The Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of a new dosing regimen for Elfabrio (pegunigalsidase alfa) for the treatment of Fabry disease, which, if approved by the European Commission, would significantly reduce the treatment burden for patients and their families [1][2]. Company Updates - Chiesi Global Rare Diseases and Protalix BioTherapeutics announced the positive CHMP opinion for the 2 mg/kg every-four-weeks (E4W) dosing regimen for Elfabrio, aimed at adult patients with Fabry disease who are stable on enzyme replacement therapy [1][2]. - Protalix is set to receive a regulatory milestone payment of $25 million from Chiesi if the E4W dosing regimen is approved by the European Commission [3]. Product Information - Elfabrio is a PEGylated enzyme replacement therapy designed to treat Fabry disease, utilizing a plant cell culture-expressed and chemically modified version of the α-Galactosidase-A enzyme [4]. - Clinical studies have shown that Elfabrio has an initial half-life of 78.9 ± 10.3 hours, indicating stable pharmacokinetic parameters [4]. Clinical Study Insights - The CHMP's positive opinion is based on results from the BRIGHT study, which assessed the safety, efficacy, and pharmacokinetics of the new dosing regimen over 52 weeks, along with an ongoing open-label extension study [2]. - The updated Population Pharmacokinetics model and exposure–response analysis further support the new dosing regimen, leveraging data from multiple clinical studies [2]. Industry Context - The approval of the new dosing regimen is seen as a critical step in expanding treatment options for patients with Fabry disease, addressing both effective management of the condition and patient preferences to minimize disruptions in daily life [2]. - The collaboration between Chiesi and Protalix highlights the commitment to advancing treatments for rare diseases, with a focus on innovative therapeutic solutions [2][19].

Core Viewpoint - Pluxee N.V. disclosed transactions on treasury shares for the period from January 19 to January 23, 2026, detailing daily trading volumes and average prices across different platforms [1]. Group 1: Treasury Share Transactions - On January 19, 2026, a total of 74,500 shares were acquired at prices ranging from €11.2200 to €11.3457 across three platforms [2]. - On January 20, 2026, 74,000 shares were acquired at prices between €11.1967 and €11.2211 [2]. - On January 21, 2026, 65,000 shares were acquired at prices between €11.9276 and €11.9452 [2]. - On January 22, 2026, 72,608 shares were acquired at prices ranging from €11.8711 to €11.9289 [2]. - On January 23, 2026, 78,137 shares were acquired at prices between €11.1290 and €11.2100 [2]. Group 2: Company Overview - Pluxee operates in 28 countries, focusing on Employee Benefits and Engagement, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [3]. - The company has over 5,600 engaged team members and serves more than 500,000 clients, 37 million consumers, and 1.7 million merchants [3]. - With over 45 years of experience, Pluxee is dedicated to positively impacting local communities and supporting employee well-being [3].